T3 Pharmaceuticals Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 21

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $502M

T3 Pharmaceuticals General Information

Description

Developer of immuno-oncology therapies designed to treat cancer patients. The company's therapies use a proprietary protein delivery platform by repurposing the bacterial type III secretion (T3S) system to treat solid cancer tumors, enabling healthcare providers to improve the lives of the patients and cure them.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Boehringer Ingelheim
Corporate Office
  • Hegenheimermattweg 167A
  • 4123 Allschwil
  • Switzerland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

T3 Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 22-Nov-2023 $502M 000.00 00000 Completed Generating Revenue
7. Later Stage VC 22-Jul-2020 000.00 000.00 Completed Generating Revenue
6. Early Stage VC 26-Sep-2019 000.00 000.00 000.00 Completed Generating Revenue
5. Grant 28-May-2019 000.00 00.000 Completed Generating Revenue
4. Accelerator/Incubator 30-Jan-2018 00000 00.000 Completed Generating Revenue
3. Angel (individual) 28-Nov-2016 00.000 00.000 00.000 Completed Startup
2. Grant $2.01M Completed Startup
1. Spin-Off 01-May-2015 Completed Startup
To view T3 Pharmaceuticals’s complete valuation and funding history, request access »

T3 Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B Preference 00,000 00.000000 000.00 000.00 00 000.00 00.000
Ordinary 00,000 00.000000 000.00 000.00 00 000.00 00.000
To view T3 Pharmaceuticals’s complete cap table history, request access »

T3 Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of immuno-oncology therapies designed to treat cancer patients. The company's therapies use a proprietary prot
Drug Discovery
Allschwil, Switzerland
21 As of 2023
000.00
00000 0000-00-00
000000&0 000.00

000000

, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
0000 000000000
Newark, CA
0 As of 0000
000.00
00000000000 000.00

000000

et, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et d
0000 000000000
Uppsala, Sweden
00 As of 0000
0000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

T3 Pharmaceuticals Competitors (59)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cellerant Therapeutics Venture Capital-Backed Newark, CA 0 000.00 00000000000 000.00
Beactica Therapeutics Venture Capital-Backed Uppsala, Sweden 00 0000000000
Anaveon Venture Capital-Backed Basel, Switzerland 00 00000 00000000000 00000
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
Gadeta Formerly VC-backed Utrecht, Netherlands 00 00.000 000000&0 00.000
You’re viewing 5 of 59 competitors. Get the full list »

T3 Pharmaceuticals Patents

T3 Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3210774-A1 Pharmaceutical combinations for treating cancer Pending 25-Mar-2021 000000000
AU-2022244124-A1 Pharmaceutical combinations for treating cancer Pending 25-Mar-2021 000000000
AU-2022244124-A9 Pharmaceutical combinations for treating cancer Pending 25-Mar-2021 000000000
EP-4314036-A1 Pharmaceutical combinations for treating cancer Pending 25-Mar-2021 000000000
EP-4313310-A1 Pharmaceutical combinations for treating cancer Pending 25-Mar-2021 A61P35/00
To view T3 Pharmaceuticals’s complete patent history, request access »

T3 Pharmaceuticals Executive Team (6)

Name Title Board Seat Contact Info
Simon Ittig Ph.D Co-Founder, Chief Executive Officer & Managing Director
Christoph Kasper Ph.D Co-Founder & Chief Scientific Officer
Marlise Amstutz Ph.D Co-Founder & Executive Director of Microbiology
Helmut Kessmann Ph.D Co-Founder & Board Member
Claire Barton Chief Medical Officer
You’re viewing 5 of 6 executive team members. Get the full list »

T3 Pharmaceuticals Board Members (3)

Name Representing Role Since
Helmut Kessmann Ph.D T3 Pharmaceuticals Co-Founder & Board Member 000 0000
You’re viewing 1 of 3 board members. Get the full list »

T3 Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

T3 Pharmaceuticals Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BASELAUNCH Accelerator/Incubator 000 0000 000000 0
Boehringer Ingelheim Venture Fund Venture Capital Minority 000 0000 000000 0
Gebert Rüf Foundation Accelerator/Incubator 000 0000 000000 0
Innosuisse Government 000 0000 000000 0
Reference Capital (Switzerland) Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

T3 Pharmaceuticals FAQs

  • When was T3 Pharmaceuticals founded?

    T3 Pharmaceuticals was founded in 2015.

  • Who is the founder of T3 Pharmaceuticals?

    Simon Ittig Ph.D, Christoph Kasper Ph.D, Marlise Amstutz Ph.D, Helmut Kessmann Ph.D, and Roger Meier are the founders of T3 Pharmaceuticals.

  • Who is the CEO of T3 Pharmaceuticals?

    Simon Ittig Ph.D is the CEO of T3 Pharmaceuticals.

  • Where is T3 Pharmaceuticals headquartered?

    T3 Pharmaceuticals is headquartered in Allschwil, Switzerland.

  • What is the size of T3 Pharmaceuticals?

    T3 Pharmaceuticals has 21 total employees.

  • What industry is T3 Pharmaceuticals in?

    T3 Pharmaceuticals’s primary industry is Drug Discovery.

  • Is T3 Pharmaceuticals a private or public company?

    T3 Pharmaceuticals is a Private company.

  • What is the current valuation of T3 Pharmaceuticals?

    The current valuation of T3 Pharmaceuticals is 00000.

  • What is T3 Pharmaceuticals’s current revenue?

    The current revenue for T3 Pharmaceuticals is 000000.

  • How much funding has T3 Pharmaceuticals raised over time?

    T3 Pharmaceuticals has raised $41.8M.

  • Who are T3 Pharmaceuticals’s investors?

    BASELAUNCH, Boehringer Ingelheim Venture Fund, Gebert Rüf Foundation, Innosuisse, and Reference Capital (Switzerland) are 5 of 9 investors who have invested in T3 Pharmaceuticals.

  • Who are T3 Pharmaceuticals’s competitors?

    Cellerant Therapeutics, Beactica Therapeutics, Anaveon, NexImmune, and Gadeta are some of the 59 competitors of T3 Pharmaceuticals.

  • When was T3 Pharmaceuticals acquired?

    T3 Pharmaceuticals was acquired on 22-Nov-2023.

  • Who acquired T3 Pharmaceuticals?

    T3 Pharmaceuticals was acquired by Boehringer Ingelheim.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »